Currently, out of the existing stock ratings of Vamil Divan - 206 which are a Buy (59.88%), 125 which are a Hold (36.34%), 13 which are a Sell (3.78%)

Vamil Divan

Work Performance Price Targets & Ratings Chart

Analyst Vamil Divan works at GUGGENHEIM and is covering the Healthcare sector with 701 price targets and ratings displayed on 33 stocks. Previously, Vamil Divan worked at MIZUHO, CREDIT SUISSE.

Vamil Divan's average stock forecast success ratio is 61.42% with an average time for price targets to be met of 243.22 days.

Most recent stock forecast was given on SAGE, Sage Therapeutics at 07-Sep-2023.

Wall Street Analyst Vamil Divan

Analyst best performing recommendations are on KRTX (KARUNA THERAPEUTICS).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%) receiving and performance score of 69.38.

Average potential price target upside

of $48.7 (45.03%) on KRTX (KARUNA THERAPEUTICS).
of $28.38 (34.49%) on JNJ (JOHNSON & JOHNSON).
of $24.14 (18.91%) on LLY (ELI LILLY AND COMPANY).

ABBV AbbVie ACAD ACADIA Pharmaceuticals AGN ALKS Alkermes plc AXSM Axsome Therapeutics BHVN Biohaven Pharmaceutical Holding Company Ltd EOLS Evolus KRTX Karuna Therapeutics LLY Eli Lilly and Company NBIX Neurocrine Biosciences PFE Pfizer PTLA SAGE Sage Therapeutics STSA Satsuma Pharmaceuticals TEVA Teva Pharmaceutical Industries AIMT BMY BristolMyers Squibb Company JNJ Johnson & Johnson CABA CFRX RVNC Revance Therapeutics AVTE CALT Calliditas Therapeutics AB Sponsored ADR CRVS Corvus Pharmaceuticals ESPR Esperion Therapeutics GLPG Galapagos NV GOSS IRWD Ironwood Pharmaceuticals KDNY MRK Merck . RLMD SCYX TVTX Travere Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Christopher Raymond (PIPER SANDLER)